Physician profile
Michelle I Uzor
NPI 1306343462
$4,837.22
in general payments reported to CMS, 2019-2025
20 companies · $3,519 in 2025
The $3,519 reported for 2025 was more than what 97% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.36 · 2021: $175 · 2022: $20.37 · 2023: $712 · 2024: $398 · 2025: $3,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,193 · Food and Beverage: $1,282 · Travel and Lodging: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,193.00 |
| Food and Beverage | $1,281.69 |
| Travel and Lodging | $154.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,363.00 | 2025 | |
| Astellas Pharma US INC | $378.45 | 2023-2024 | Veozah, Myrbetriq |
| Baxter Healthcare | $174.50 | 2021 | |
| Hologic Sales and Service, LLC | $146.70 | 2023-2024 | Acessa Provu System, Aptima |
| Pfizer INC. | $117.27 | 2023-2025 | |
| Coopersurgical, INC. | $95.42 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Mayne Pharma Commercial LLC | $91.19 | 2023 | |
| Abbvie INC. | $61.83 | 2023-2025 | Liletta |
| Organon LLC | $56.08 | 2023-2025 | Nexplanon |
| Biogen, INC. | $50.75 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $46.52 | 2023-2025 | |
| Ethicon US, LLC | $45.37 | 2024 | Enseal, Vistaseal |
| Genentech USA, INC. | $44.80 | 2024 | Alecensa, Rozlytrek, Tecentriq |
| Shield Therapeutics INC | $40.14 | 2023 | Accrufer |
| Adaptive Biotechnologies Corporation | $34.02 | 2024 | Clonoseq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $32.33 | 2023-2024 | Myfembree |
| Aspira Women'S Health INC | $24.46 | 2024 | Ova1 |
| Janssen Biotech, INC. | $17.25 | 2024 | Darzalex |
| Boston Scientific Corporation | $13.36 | 2020 | |
| Meditrina | $3.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Uzor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.